PHP36 THE AVAILABILITY AND FUNDING OF ORPHAN DRUGS IN BOSNIA AND HERZEGOVINA IN COMPARISON WITH NEIGHBORING COUNTRIES
Catic T, Bajramovic A Society for Pharmacoeconomics and Outcomes Research in Bosnia and Herzegovina, Sarajevo, Bosnia OBJECTIVES: The aim was to examine the current availability and funding of orphan drugs in both entities of B&H and compare the obtained data with neighboring countries (Croatia, Serbia and Montenegro) and the EU. METHODS: We have analyzed the current published list of medicines in B&H and neighboring countries. We have compared the drugs that have the status of orphans according to the Orphanet report. RESULTS: In BiH there are no lists of orphan drugs while some of them are included in the list of chemotherapeutic agents and drugs for specifi c diseases (RS). Only Croatia has made a special list of expensive medicines containing drugs for treatment of hereditary enzyme defi ciency. All countries have imatinib reimbursed. Only in the RS and Serbia thalidomide is reimbursed, and Serbia has listed sildenafi l, zinc acetate and busulfan. Present practice in all countries is that patients apply individualy for orphan drugs reimbursement approval to HIFs. CONCLUSIONS: In order to improve access to orphan drugs it is necessary to adopt a national policy which will be harmonized with the EU. Decisions on the reimbursement must be based on real possibilities and it is necessary to implement appropriate registries for future resource allocation decissions.
PHP37 THE IMPACT OF UNIVERSAL COVERAGE ON EQUITY IN HEALTH CARE FINANCE AND FINANCIAL RISK PROTECTION IN THAILAND
Prakongsai P International Health Policy Program (IHPP), Nonthaburi Province, Thailand OBJECTIVES: To assess the impact of achieving universal coverage (UC) on equity in health care fi nance and on fi nancial risk protection from expensive medical care costs for Thai households. METHODS: Secondary data analyses using nationally representative household surveys conducted by National Statistical Offi ce, the Socioeconomic Survey 2000 (prior to UC) and 2002 -2006 to analyze changes in progressivity of overall health care fi nance and different health fi nancing sources.
The share of households facing catastrophic health expenditure in the poorest and richest income quintiles prior to and after achieving UC was also assessed. RESULTS: The fi nancing of the Thai health care system became more equitable after the UC policy was implemented. Improved fi nancial risk protection after achieving UC was observed due to the comprehensive benefi t package and literally free at point of services. The Kakwani index value for overall health care fi nance changed from −0.0038 (regressive) in 2000 to positive (progressive) values of 0.0014, 0.0342 and 0.0406 in 2002, 2004 and 2006, respectively . The share of households facing catastrophic spending on health decreased from 5.4% in 2000 to 2.0% in 2006. The 1 st (poorest) quintile experienced a 77.5% reduction in the proportion of households facing catastrophic health expenditure, while there was a 41% reduction in the share of households in the 5 th (richest) quintile. CONCLUSIONS: Factors contributing to equitable health fi nance are: the increasing share of progressive fi nancing sources in particular direct tax; the decreasing share of the regressive out-of-pocket payments for health. Using general taxation to fi nance the poor and the informal sector not only helps reach universal coverage, it is also the most progressive fi nancing source. Various factors contribute to the low incidence of catastrophic heath expenditure: comprehensive benefi t package covering almost all health services which are free at point of use, and well-functioning primary care providers.
PHP38 HOW EQUITABLE OF HEALTH SERVICE USE AND GOVERNMENT SUBSIDIES IN THAILAND AFTER ACHIEVING UNIVERSAL COVERAGE?
Prakongsai P International Health Policy Program (IHPP), Nonthaburi Province, Thailand OBJECTIVES: To assess trends of equity in health service use and distribution of government subsidies to ambulatory services and hospitalization across income gradients of the Thai population prior to and after implementation of the universal coverage (UC) policy in 2002 and explained how such equity has been achieved. METHODS: Secondary data analyses using nationally representative household surveys conducted by National Statistical Offi ce, the Health and Welfare Survey (HWS) 2001 (prior to UC) and 2003 -2007 to analyze equity in health service use at different health care levels and the distribution of government subsidies for health. The analytical approach employed a standard method for health equity analysis of the large scale household surveys proposed by O'Donnell et al. RESULTS: Outpatient and inpatient service use of the Thai health systems were both pro-poor before achieving UC in 2002 due to various government interventions in extending health insurance coverage and countrywide distribution of health service infrastructure, and the signifi cant increase in human resource production. After the UC policy implementation, the propoor service utilization was further progressed. Overall, public subsidies for health were found to be pro-poor for both outpatient and inpatient services with the concentration indexes of −0.226, −0. 186 and −0.180, in 2003, 2006 and 2007, respectively. District health provider networks, in particular health centres, district and provincial hospitals are the major determinants of the pro-poor distribution of service utilization and public subsidies, due to their geographical proximity and better access by the poor. A comprehensive benefi t package and the provision of services that are free at the point of use resulted in the pro-poor benefi t incidence. CONCLUSIONS: The pro-poor outcome is the result of an availability of functional primary care at the district level, and implementation of the UC policy which focuses on contracting primary care networks at the district level.
PHP39 A COMPARISON OF GENERIC AND ORIGINATOR BRAND DRUG PRICES BETWEEN JORDAN AND THE UNITED KINGDOM
El-Dahiyat F 1 , Kayyali R 1 , Alabbadi I 2 1 Kingston University, London, UK; 2 University of Jordan, Amman, Jordan OBJECTIVES: The study aimed to compare the retail prices of generics and originator brand for fi ve drugs between Jordan and United Kingdom and to investigate the relation between number of generics available, retail price of originator and generic (s) and the effect of time in the market on these prices. METHODS: Prices of originators and generics and the number of generics available in each market were obtained from the Jordanian Food and Drug Administration, Royal Pharmaceutical Society of Great Britain, British National Formulary and Chemist & Druggist generics list. The prices were converted to British Pounds expressed per one dose unit. All data was tabulated in spreadsheets; prices were compared between the two countries at different preset times. RESULTS: The generics of all drugs investigated appeared in the Jordanian market before patent expiry of their originator worldwide due to lack of patency regulations in Jordan at the launch time of drugs under investigation (before 2004). Unlike the UK, the prices of originator drugs in Jordan did not change when the fi rst generic was introduced to the market. The price of generic drugs have dropped dramatically in the UK at time of fi rst generic launch approximately by 90% compared to 15% in Jordan. There was no apparent correlation between the numbers of generics available or the number of years of fi rst generic being in the market and the prices of the drugs investigated in both countries. The current prices of all investigated drugs in Jordan are higher than the UK particularly for the generics. CONCLUSIONS: Although much lower income per capita in Jordan, generic drugs are more expensive than the equivalent prices of same drugs in the UK
